Gastrin I (human): Advancing CCK2 Receptor Signaling and Intestinal Organoid Pharmacology

Introduction

Gastrin I (human) is a pivotal endogenous regulatory peptide, integral to our understanding of gastrointestinal physiology and the molecular mechanisms underlying gastric acid secretion. As both a gastric acid secretion regulator and a CCK2 receptor agonist, this peptide (CAS: 10047-33-3; MW: 2098.22 Da) occupies a central role in the study of receptor-mediated signal transduction and the modulation of proton pump activity in parietal cells. With the rise of advanced in vitro models such as human pluripotent stem cell-derived intestinal organoids, Gastrin I (human) has emerged not only as a research tool for dissecting acid secretion pathways, but also as a valuable probe for drug development and translational studies. This article goes beyond the established applications—providing a mechanistic deep dive into Gastrin I’s action in next-generation organoid systems, and critically evaluating its role in the context of pharmacokinetic and receptor signaling research. This perspective builds upon, but distinctly expands, the current content landscape by focusing on the precise integration of Gastrin I in translational intestinal organoid pharmacology.

Biochemical Properties and Quality Control of Gastrin I (human)

Gastrin I (human) is supplied by APExBIO as a white lyophilized solid, formulated for maximal stability and research-grade purity (≥98%, verified by HPLC and mass spectrometry). Notably insoluble in water and ethanol, but readily soluble in DMSO at concentrations ≥21 mg/mL, the product’s unique solubility profile facilitates its use in diverse in vitro assays. For optimal performance, it should be stored desiccated at -20°C, and working solutions are best prepared immediately prior to use to ensure functional integrity. These rigorous quality controls make Gastrin I (human) (SKU: B5358) a trusted standard for reproducible, high-fidelity research.

Mechanism of Action: CCK2 Receptor Agonism and Proton Pump Activation

Receptor-Mediated Signal Transduction

Functioning as a potent CCK2 receptor agonist, Gastrin I (human) interacts with CCK2 (cholecystokinin B/gastrin) receptors prominently expressed on gastric parietal cells. Upon ligand binding, the CCK2 receptor—an integral G protein-coupled receptor (GPCR)—activates downstream phospholipase C-mediated signaling cascades. This results in the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), mobilizing intracellular calcium stores and activating protein kinase C.

The culmination of this cascade is the stimulation of the H⁺/K⁺-ATPase proton pump at the apical membrane of parietal cells, which drives the secretion of gastric acid into the stomach lumen. This tightly regulated process is central to digestion and the maintenance of gastric homeostasis. In vitro, the precise control enabled by Gastrin I (human) allows researchers to model and dissect each step of this pathway, facilitating high-resolution studies in both two-dimensional cultures and sophisticated 3D organoid systems.

Comparative Mechanistic Insights

While previous articles—such as "Gastrin I (human): Unraveling Proton Pump Activation in N..."—have detailed the peptide’s role in proton pump activation and receptor signaling, this article provides a broader translational focus by situating these mechanisms within the context of advanced intestinal organoid pharmacology and drug metabolism research.

Gastrin I (human) in the Era of Intestinal Organoids: Expanding Functional Paradigms

Intestinal Organoids as Next-Generation In Vitro Models

The recent development of human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) represents a transformative advance for gastrointestinal physiology studies and preclinical drug evaluation. Unlike traditional Caco-2 cell models—limited by their cancer-derived origin and suboptimal expression of drug-metabolizing enzymes—hiPSC-IOs can recapitulate the complexity of the intestinal epithelium, including mature enterocytes, goblet cells, enteroendocrine cells, and Paneth cells. This is achieved through staged differentiation protocols and 3D culture systems, as meticulously described in a landmark study by Takumi Saito et al. (European Journal of Cell Biology, 2025).

These organoids exhibit functional cytochrome P450 activity, transporter expression, and maintain the self-renewal capacity characteristic of intestinal stem cells (ISCs). Critically, they provide a physiologically relevant platform for evaluating drug absorption, metabolism, and toxicity, overcoming the species-specific limitations of animal models and the oversimplification inherent to monolayer cultures.

The Role of Gastrin I (human) in Organoid Maturation and Functional Assays

Gastrin I (human) is instrumental in recapitulating physiologic secretory responses in organoid systems. By introducing this gastric acid secretion regulator to hiPSC-IOs, researchers can:

• Precisely activate the CCK2 receptor signaling axis, enabling the study of receptor-mediated signal transduction in a human-relevant context.
• Model and quantify proton pump activation and downstream acid secretion, linking molecular inputs to functional outputs.
• Investigate the interplay between enteroendocrine signaling and epithelial cell differentiation/maturation.
• Screen for pharmacological modulators of CCK2-mediated pathways, facilitating drug discovery for gastrointestinal disorders.

Importantly, the high purity and lot-to-lot consistency of APExBIO’s Gastrin I (human) ensures reproducibility across complex, multi-factorial organoid experiments—addressing a key challenge highlighted in scenario-driven laboratory guidance (see "Gastrin I (human) in GI Organoids: Data-Driven Lab Solutions"). While that article emphasizes workflow robustness and vendor reliability, our focus is on the mechanistic depth and novel pharmacological insights unlocked by these organoid systems.

Comparative Analysis: Advancing Beyond Conventional and Existing Approaches

Strengths and Limitations of Traditional Models

Historically, studies of gastric acid secretion and receptor signaling have relied on animal models or immortalized cell lines (e.g., Caco-2). However, these platforms are constrained by interspecies variation and incomplete recapitulation of human transporter and enzyme expression, as detailed in Saito et al. (2025). Consequently, the translation of mechanistic findings to clinical contexts has often been limited.

Organoids + Gastrin I: A Paradigm Shift

The integration of Gastrin I (human) into hiPSC-IOs surmounts these limitations by providing:

• Authentic human cellular context for CCK2 receptor signaling studies.
• Quantitative readouts of proton pump activation and downstream effects tailored to patient-specific or disease-relevant genotypes.
• Enhanced capacity for gastrointestinal disorder research, including the modeling of hypergastrinemia, peptic ulcer disease, and atrophic gastritis.

Whereas articles like "Gastrin I (human): Mechanistic Precision and Translational..." offer guidance for integrating Gastrin I in translational workflows, our analysis delves deeper into the organoid-based pharmacokinetic models, illuminating how the synergy between this peptide and advanced 3D systems drives innovation in both experimental and preclinical research.

Advanced Applications: Pharmacokinetics, Disease Modeling, and Drug Discovery

Pharmacokinetic Profiling in Organoid Systems

With the ability to recapitulate mature enterocyte function—including CYP-mediated metabolism and multidrug transporter activity—hiPSC-IOs represent an ideal platform for pharmacokinetic studies. Gastrin I (human) can be used to:

• Induce physiologically relevant acid secretion, which is critical for the assessment of oral drug dissolution and absorption.
• Model the dynamic interplay between gastric acid, mucosal defense, and epithelial barrier integrity.
• Evaluate the impact of CCK2 receptor agonism on the expression and function of drug-metabolizing enzymes and transporters.

This approach enables researchers to bridge basic receptor biology with applied pharmacology—an area that existing content has yet to fully explore.

Gastrointestinal Disorder Research and Therapeutic Mechanisms

Gastrin I (human) is invaluable for elucidating pathophysiological mechanisms in a range of diseases:

• Hypergastrinemia and Zollinger-Ellison syndrome: Modeling excess Gastrin I-induced acid secretion and its downstream consequences.
• Atrophic gastritis: Studying the loss of parietal cell responsiveness and receptor desensitization.
• Peptic ulcer disease: Investigating the disruption of mucosal defense mechanisms in the presence of heightened acid secretion.

Furthermore, by leveraging the modularity of organoid cultures, researchers can introduce genetic or pharmacologic perturbations (e.g., CCK2 antagonists, proton pump inhibitors) to dissect therapeutic mechanisms and optimize intervention strategies. This positions Gastrin I (human) at the nexus of gastric acid secretion pathway research and translational drug development.

Comparison with Existing Guidance

While articles such as "Gastrin I (human): Precision Tool for Gastric Acid Secret..." focus on the peptide's reliability and efficacy in standard in vitro systems, our work uniquely highlights the integration of Gastrin I into advanced, patient-specific organoid models—expanding its application from experimental workflows to human-relevant pharmacokinetics and disease modeling.

Practical Considerations: Handling, Storage, and Experimental Design

Given its insolubility in water and ethanol, it is crucial to dissolve Gastrin I (human) in DMSO at concentrations ≥21 mg/mL. Immediate preparation and use of working solutions maximize peptide integrity and activity. For long-term research continuity, storing the lyophilized product desiccated at -20°C preserves both purity and bioactivity. These protocols—supported by APExBIO's stringent quality control—ensure reliable performance in both exploratory and high-throughput applications.

Conclusion and Future Outlook

Gastrin I (human) has transcended its role as a classical gastric acid secretion regulator, evolving into a critical tool for interrogating CCK2 receptor signaling, proton pump activation, and the molecular underpinnings of gastrointestinal physiology. Its integration within hiPSC-derived intestinal organoids opens new horizons for pharmacokinetic profiling, disease modeling, and drug discovery—areas that are only beginning to be fully realized. This synthesis of biochemical rigor, advanced in vitro models, and translational relevance positions Gastrin I (human) as an indispensable asset for the next generation of gastrointestinal research.

By building upon mechanistic and workflow-focused content, and offering a distinct perspective centered on organoid pharmacology, this article aims to guide researchers toward innovative experimental paradigms—shaping the future of gastrointestinal disorder research and therapeutic intervention.